Evidence map›Paper›PMID 35749694›Full record

ArticlePloS one2022

Bicarbonate concentration as a predictor of prognosis in moderately severe COVID-19 patients: A multicenter retrospective study.

Ken-Ei Sada, Ryohei Yamamoto, Akihiko Yano, Atsushi Miyauchi, Masafumi Kawamura, Hideki Ito

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ken-Ei SadaDepartment of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Japan.ORCID 0000-0003-1020-0818
Ryohei YamamotoDepartment of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Akihiko YanoDepartment of General Medicine, Kochi Health Sciences Center, Kochi, Japan.
Atsushi MiyauchiDepartment of Internal Medicine, Kochi Prefectural Hata-Kenmin Hospital, Sukumo, Japan.
Masafumi KawamuraDepartment of Internal Medicine, Kochi Prefectural Hata-Kenmin Hospital, Sukumo, Japan.
Hideki ItoDepartment of General Medicine, Kochi Health Sciences Center, Kochi, Japan.
Makino Botanical Garden · JPKyoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (COVID-19) patients reportedly have high bicarbonate concentration. However, its relationship to the disease progression are obscure.

methodsIn this two-center retrospective study, we included COVID-19 patients with moderate severity between March 2020 and May 2021. We classified patients into three groups according to bicarbonate concentrations: high (>27 mEq/L), normal (21 to 27 mEq/L), and low (<21 mEq/L). The primary outcome was the time to clinical worsening defined by the requirement of intubation or death during 90 days. We evaluated high or low bicarbonate concentration during the clinical course related to the primary outcome using multivariable Cox proportional hazard models.

resultsOf the 60 participants (median age 72 years), 60% were men. Participants were classified into high (13 patients), normal (30 patients), and low (17 patients) groups. Clinical worsening occurred in 54% of patients in the high group, 23% in the normal group, and 65% in the low group. Both high and low groups were associated with a higher clinical worsening rate: HR, 3.02 (95% CI, 1.05 to 8.63) in the high group; 3.49 (95% CI: 1.33 to 9.12) in the low group.

conclusionMonitoring of bicarbonate concentrations may be useful to predict the prognosis.

Indexed as

BicarbonatesCOVID-19AgedFemaleHumansMalePrognosisProportional Hazards ModelsRetrospective StudiesBicarbonates

Identifiers

PMID35749694
PMCPMC9232226
OpenAlexW4283388126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.